Abstract
Nuclear inositide signalling is implicated in normal and pathological cell proliferation and differentiation in several distinct models. Among the key molecules of nuclear inositide pathways, phosphoinositide-phospholipase (PI-PLC) C β1 is essential for regulating hematopoiesis, particularly along myeloid and erythroid lineage. Moreover, Akt activation is associated with protein synthesis, via mTOR pathway, and with erythroid induction, through PI-PLCγ1 activation. Myelodysplastic syndromes (MDS) are a series of heterogeneous diseases characterized by ineffective hemopoiesis, with a variable risk of evolution into acute myeloid leukemia (AML). Therapeutic approaches for MDS include demethylating agents, such as azacitidine, aiming at reducing cell proliferation, and erythropoietin, useful for sustaining a normal erythropoiesis. In the last few years, a role for nuclear inositide signalling as a therapeutic target in MDS has been disclosed, in that PI-PLCβ1 increase is associated with azacitidine responsiveness, even when this drug is used in combination with other agents, and Akt is specifically activated in MDS at higher risk of AML evolution. On the other hand, recent data demonstrated that inositide signalling can also be involved in erythroid therapy, given the inhibitory effect of erythropoietin on PI-PLCβ1 and the activation of Akt/PI-PLCγ1 pathway, following the administration of erythropoietin. Here, we review the strategic role of nuclear inositide signalling in MDS, in pathogenesis and therapy.
Keywords: Akt, azacitidine, erythropoietin, erythroid differentiation, myelodysplastic syndromes, myeloid differentiation, nuclear inositides, phospholipase Cβ1.
Mini-Reviews in Medicinal Chemistry
Title:Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy
Volume: 14 Issue: 11
Author(s): Lucia Manzoli, Sara Mongiorgi, Cristina Clissa, Carlo Finelli, Anna Maria Billi, Alessandro Poli, Marilisa Quaranta, Lucio Cocco and Matilde Y. Follo
Affiliation:
Keywords: Akt, azacitidine, erythropoietin, erythroid differentiation, myelodysplastic syndromes, myeloid differentiation, nuclear inositides, phospholipase Cβ1.
Abstract: Nuclear inositide signalling is implicated in normal and pathological cell proliferation and differentiation in several distinct models. Among the key molecules of nuclear inositide pathways, phosphoinositide-phospholipase (PI-PLC) C β1 is essential for regulating hematopoiesis, particularly along myeloid and erythroid lineage. Moreover, Akt activation is associated with protein synthesis, via mTOR pathway, and with erythroid induction, through PI-PLCγ1 activation. Myelodysplastic syndromes (MDS) are a series of heterogeneous diseases characterized by ineffective hemopoiesis, with a variable risk of evolution into acute myeloid leukemia (AML). Therapeutic approaches for MDS include demethylating agents, such as azacitidine, aiming at reducing cell proliferation, and erythropoietin, useful for sustaining a normal erythropoiesis. In the last few years, a role for nuclear inositide signalling as a therapeutic target in MDS has been disclosed, in that PI-PLCβ1 increase is associated with azacitidine responsiveness, even when this drug is used in combination with other agents, and Akt is specifically activated in MDS at higher risk of AML evolution. On the other hand, recent data demonstrated that inositide signalling can also be involved in erythroid therapy, given the inhibitory effect of erythropoietin on PI-PLCβ1 and the activation of Akt/PI-PLCγ1 pathway, following the administration of erythropoietin. Here, we review the strategic role of nuclear inositide signalling in MDS, in pathogenesis and therapy.
Export Options
About this article
Cite this article as:
Manzoli Lucia, Mongiorgi Sara, Clissa Cristina, Finelli Carlo, Billi Maria Anna, Poli Alessandro, Quaranta Marilisa, Cocco Lucio and Follo Y. Matilde, Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy, Mini-Reviews in Medicinal Chemistry 2014; 14 (11) . https://dx.doi.org/10.2174/1389557514666141013125936
DOI https://dx.doi.org/10.2174/1389557514666141013125936 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multidrug Transporters as Drug Targets
Current Drug Targets Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control
Current Cancer Therapy Reviews Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies in Non-Small Cell Lung Cancer: Proven Concepts and Unfulfilled Promises.
Current Cancer Drug Targets P53 Mdm2 Inhibitors
Current Pharmaceutical Design Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Radiation Therapy in the Management of Lung Cancer
Current Respiratory Medicine Reviews The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Tumor Stroma Manipulation By MSC
Current Drug Targets Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials
Reviews on Recent Clinical Trials